Quick Takeaways
- ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL).
- Disclosed ownership: 13%.
- Date of event: 31 Dec 2024.
Quoteable Key Fact
"ARCH Venture Fund IX, L.P. disclosed 13% ownership in Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL) on 31 Dec 2024."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, L.P. | its General Partner | |
| ARCH Venture Fund IX Overage, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX Overage, L.P. | its General Partner | |
| ARCH Venture Partners IX, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX Overage, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX, LLC | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell | |
| Clinton Bybee | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee | |
| Robert Nelsen | 13% | 36,597,716 | 185,000 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen |